In a Phase I/II open-label study of patients with multiple sclerosis and amyotrophic lateral sclerosis, mesenchymal stem cell transplantation was found to be safe and induced an early immunonologic response.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content